NCT06016010尚未招募2 期
Efficacy and Safety of USL for Dry Eye Disease (DED): a Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2 Clinical Trial
Chan-Sik Kim0 个研究点目标入组 120 人开始时间: 2024年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
- 主要终点
- TBUT(Tear break-up time)
研究概览
简要总结
The objective is to compare the USL and placebo in terms of efficacy and safety, and to determine the appropriate dosage.
详细描述
This study is a phase 2, dose-finding, double-blind, randomized placebo-controlled trial of two different doses of USL compared with placebo. A total of 120 patients, aged over 19 years, with Corneal staining score(Oxford grading) ≥ 2 or TBUT < 10 sec and OSDI ≥ 10 points will be recruited at Daejeon University Daejeon Korean Medicine Hospital. Patients will take medications two times daily for 12 weeks, with 5 visiting days(screening, week 0, week 6, week 12, week 14).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged over 19
- •Screening both eyes, the corrected visual acuity is 0.2 or more
- •Subjects with Fluorescein Corneal Staining score (Oxford grading) ≥ 2 or TBUT test ≤10 at screening
- •Subjects with OSDI ≥ 13
- •Subjects who voluntarily agreed to participate in this clinical study in written form
排除标准
- •Current or history of ocular disorders possibly affecting the study results (ocular surgery, trauma, diseases) as followings within 2 months:
- •Abnormal eyelid function: disorders of the eyelids or eyelashes
- •Ocular allergies or currently under the treatment of allergic diseases of the eye (topical ocular mast cell stabilizer, antihistamine use, etc.)
- •Cicatricial keratoconjunctivitis caused by herpetic keratopathy, conjunctival scarring (alkali damage, Steven-Johnson syndrome, cicatricial pemphigoid), pterygium, pinguecula, lack of congenital lacrimal, neurogenic keratitis, keratoconus, corneal transplantation
- •Those with acute eye inflammation/infection within 1 month
- •Those who have undergone eye surgery (including LASIK/LASIK) within 3 months
- •Those who had taken lacrimal punctal occlusion, cauterization of the punctum, or intense pulsed light procedure within 3 months
- •Those who wear contact lenses within 72 hours of screening or plan to wear contact lens during the study period
- •Intraocular pressure (IOP)> 25 mmHg in more than one side
- •Autoimmune disease (e.g., Sjogren's syndrome, Rheumatoid arthritis, systemic lupus erythematosus, Graves' disease)
- •Those who have used cyclosporine or diquafosol use in any form (systemic, topical) within 1 month
- •Medical condition or history within 1 month to be treated with topical agents besides artificial tears (glaucoma, ocular allergy, ocular inflammation/infectious disease, etc.)
- •Those who have taken or are taking steroid drugs or immunosuppressants (Azathioprine, Tacrolimus, Cyclosporin, Mycophenolate mofetil etc.) that may affect immune function within 3 months prior to screening
- •Those who had taken antihypertensive drugs such as antihistamine and beta blockers, diuretics, antidepressants (especially tricyclic antidepressants, Parkinson's treatment drugs, etc.) that can worsen dry eye cannot participate in this study
- •Severe abnormal liver function tests (Alanine transaminase (ALT) or Aspartate transaminase (AST) values ≥ 2 times the upper limit of normal) and abnormal renal function (Creatinine values ≥ 2 times the upper limit of normal)
- •Genetic disorders, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •Comorbidities that may interrupt the treatment of cancers or clinically significant disorders of the kidney, liver, psychiatric system, cardiovascular system, respiratory system, endocrine system, and central nervous system, the safety assessment, or completion of this clinical study
- •Unregulated hypertension (high blood pressure of 160 mmHg in the condenser or high blood pressure exceeding 100 mmHg in the relaxation period)
- •Unregulated diabetes (fasting blood sugar (FBS) exceeding 180 mg/dL)
- •Hepatitis A (active) or hepatitis B (active) or hepatitis C
- •History of hypersensitivity reaction to active ingredients or excipients of the investigational product
- •History of excessive alcohol use or drug addiction
- •Pregnant or lactating women
- •Those who did not agree to use contraception by medically permitted methods (e.g., surgical treatment of infertility, intrauterine device, condom or diaphragm, and injectable or insertable contraceptives) during the period from dosing of the investigational product to 90 days after the clinical study, among female subjects of childbearing potential and male subjects with the female partner
- •Those who had experience of participating in a different clinical study within 4 weeks prior to participation in this clinical study
- •Subjects who were determined to be ineligible to participate in this study
研究组 & 干预措施
Standard-dose USL group
Experimental
2 tablets(1 USL, 1 placebo) b.i.d for 12 weeks
干预措施: USL (Drug)
Standard-dose USL group
Experimental
2 tablets(1 USL, 1 placebo) b.i.d for 12 weeks
干预措施: USL Placebo (Drug)
High-dose USL group
Experimental
2 tablets(2 USL) b.i.d for 12 weeks
干预措施: USL (Drug)
Placebo group
Placebo Comparator
2 tablets(2 placebo) b.i.d for 12 weeks
干预措施: USL Placebo (Drug)
结局指标
主要结局
TBUT(Tear break-up time)
时间窗: Screening, 6 week, 12 week, 14 week
The tear break-up time test measures the time in seconds. The time is from the last blinking to the point of tear layer defect or streak-like defect after blinking the eye with 1% of fluorescein. 10 seconds or more as normal, between 5 and 10 seconds as mild dry eye syndrome, and 5 seconds or less as severe dry eye syndrome.
次要结局
- OSDI(Ocular Surface Disease Index)(Screening, 6 week, 12 week, 14 week)
- VAS(Visual analog scale)(0 week, 6 week, 12 week, 14 week)
- Schirmer's test(0 week, 6 week, 12 week, 14 week)
- Meibomian gland test(0 week, 6 week, 12 week, 14 week)
- Fluorescein corneal staining score - Oxford grading(Screening, 6 week, 12 week, 14 week)
- SPEED-II (Standard Patient Evaluation for Eye Dryness-II)(0 week, 6 week, 12 week, 14 week)
- Biomarkers(0 week, 12 week)
研究者
Chan-Sik Kim
Principal Investigator
Korea Institute of Oriental Medicine
相似试验
已完成
2 期
Safety and Efficacy of TOP1630 for Dry Eye SyndromeDry Eye SyndromeNCT03088605ORA, Inc.69
已完成
2 期
Study of TOP1630 for Dry Eye SyndromeDry Eye SyndromeNCT03833388Topivert Pharma Ltd202
已完成
1 期
IVIG-eye Drops Treatment for Dry Eye DiseaseDry EyeNCT03992482Sandeep Jain, MD27
已完成
2 期
Phase 2 Study of KLS-0611 in Patients With Dry Eye SyndromesDry Eye SyndromesNCT00721656Kissei Pharmaceutical Co., Ltd.80
已完成
4 期
Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry EyeDry EyeNCT05692739Barbara Burgos Blasco116